Clinical trials: Livedo Vasculitis
Raynaud Disease, Raynaud Disease Secondary to Scleroderma
Lab Study of MQX-503 in Treatment of Raynaud's
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin…
- Conditions
- Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
- Trial name
- NCT00253331
- Testing
- topical organogel with nitroglycerin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- MediQuest Therapeutics
Raynaud Phenomenon, Raynaud Disease
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
The purpose of this study is to analyze the effects of an intervention with galvanic electrical current on the number of attacks , temperature, pain, peripheral blow flow and upper limb functionality in patients with Raynaud's…
- Trial name
- NCT03699436
- Testing
- Electrotherapy with Galvanic Current, Control without Electric Stimulation Therapy
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Universidad de Granada
Raynaud's Disease
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
Diosmiplex is a product marketed for the management of diseases due to venous and microvascular dysfunction. Raynaud's phenomenon is a disorder of characterized by spasm of small arteries and impaired microvascular flow.
- Trial name
- NCT02683408
- Testing
- diosmiplex
- Where
- 11 sites in United States
- Volunteers
- 87 people
- Sponsor
- Primus Pharmaceuticals
Raynaud's Disease
Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease
To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.
- Trial name
- NCT00528242
- Testing
- SLx-2101
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Response Pharmaceuticals
Raynaud Phenomenon
Follow-up of SPTS in Patients With Raynaud's Phenomenon
Background: Raynaud's phenomenon is a vasospasm of the extremities, leading to extensive discomfort in daily life and potentially severe ischemia. Some patients are resistant to conventional vasodilatory drug treatment.
- Trial name
- NCT04015193
- Testing
- Single-port thoracoscopic sympathicotomy (patient care)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- University Medical Center Groningen
Cold Hypersensitivity, Vascular System Injuries
Treatment of Frostbite Sequelae With Botulinum Toxin A
Background Digital vasospasm as part of frostbite sequelae is comparable to the vasospastic disorders found in Raynaud's phenomenon which has been successfully treated with Botulinum toxin type A injections in the palm of the…
- Conditions
- Cold Hypersensitivity, Vascular System Injuries, Vibration; Disorder, Sensory Disorders
- Trial name
- NCT06460194
- Testing
- Botuinum toxin
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Secondary Raynaud's Phenomenon
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of digital ulcers related to secondary Raynaud's phenomenon associated with systemic scleroderma
- Trial name
- NCT02356809
- Testing
- Neovasculgen
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Artgen Biotech
Livedo Vasculitis, Livedoid Vasculitis
Correlation of Genetic Polymorphism and Livedo Vasculitis
Livedo vasculitis is disease with recurrent courses of painful foot or ankle ulcerations, followed by healed white scars. The actual mechanism of its pathophysiology is not yet clear.
- Conditions
- Livedo Vasculitis, Livedoid Vasculitis, Livedoid Vasculopathy, Genetic Pleomorphism
- Trial name
- NCT00975871
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Raynaud Disease, Raynaud Phenomenon
Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
Patients with Raynaud's disease have an increased tendency of chest pain and migraine, and studies indicate that the disease might be associated with increased cardiovascular morbidity and mortality.
- Conditions
- Raynaud Disease, Raynaud Phenomenon, Hand and Arm Vibration Syndrome, Diabetes Mellitus
- Trial name
- RaynAUT (NCT03094910)
- Testing
- Examination of vibration perception threshold in fingertips, Ewing's tests, Tilt table test
- Where
- Denmark
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Raynaud's Phenomenon
MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison
The purpose of this clinical study is to compare the pharmacokinetic profiles of a topical cream formulation of 0.9% nitroglycerin, MQX 503, and Nitroglycerin Ointment 2%, USP.
- Trial name
- NCT00841594
- Testing
- nitroglycerin 0.9 % (MXQ-503), Nitroglycerin ointment 2%, USP
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Raynaud Phenomenon
Application for Monitoring and Evaluation of Raynaud's Phenomenon
To evaluate the feasibility of using a smartphone application for monitoring and evaluation of Raynaud's Phenomenon.
- Trial name
- RaynaudMoni (NCT03984422)
- Testing
- Smartphone application
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Grenoble
Raynaud's Phenomenon
Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits…
- Trial name
- REINO (NCT01315899)
- Testing
- ORM-12471 30mg, ORM-12471
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Orion Corporation, Orion Pharma
Raynaud's Phenomenon Isolated Primary, Raynaud's Phenomenon (Secondary)
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.
The investigators seek to perform a comparative transcriptome analysis of TRP channels residing in the skin between primary and scleroderma secondary Raynaud's phenomenon and healthy subjects.
- Conditions
- Raynaud's Phenomenon Isolated Primary, Raynaud's Phenomenon (Secondary), Healthy
- Trial name
- TRP (NCT03211325)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Buerger Disease, Raynaud Syndrome
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease.
- Trial name
- BETOX (NCT05698979)
- Testing
- BOTOX INJECTION
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Toulouse
Raynaud Disease, Raynaud's Phenomenon
A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)
This trial will test the efficacy of brief periods of controlled limb ischemia (remote ischemic preconditioning, RIPC) as an effective treatment of patients with Raynaud's Phenomenon (RP).The hypothesis of this trial is that due…
- Trial name
- NCT02506062
- Testing
- Manual blood pressure cuff inflation over brachial artery
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
CREST Syndrome, Calcinosis Cutis
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Background CREST is an acronym for the cardinal clinical features of the syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and part of the heterogeneous group of sclerodermas.
- Conditions
- CREST Syndrome, Calcinosis Cutis, Raynaud Phenomenon
- Trial name
- NCT03972566
- Testing
- INOMAX
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- RoseLab Skin Optics Laboratory
Raynaud's Disease
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Published reports and our previous work support our hypothesis that symptomatic patients experience relief of pain and…
- Trial name
- NCT01309802
- Testing
- onabotulinum toxin type-A
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Southern Illinois University
Microstomia, Scleroderma
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
The principal objective is to measure the degree to which oral microstomia caused by sclerosing skin disease improves after treating patients with local hyaluronidase injections.
- Conditions
- Microstomia, Scleroderma, CREST Syndrome, Scleromyxedema
- Trial name
- NCT04656704
- Testing
- hyaluronidase injected intradermally
- Sponsor
- Brigham and Women's Hospital
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Scleroderma, Raynaud's Syndrome
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
This is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of Botulinum toxin A (Onabotulinumtoxin A) in treating scleroderma-associated Raynaud's syndrome.
- Trial name
- NCT02165111
- Testing
- Onabotulinumtoxin A, sterile saline solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University